HLA-DQA1

Gene description

The HLA-DQA1 gene encodes a protein that plays an important role in the immune system. It helps the immune system distinguish the body’s own proteins from proteins made by foreign invaders such as viruses and bacteria (Ref).

Mutations of this gene can cause many different autoimmune disorders, diabetes, celiac disease, narcolepsy, and arthritis (Ref).

At least two specific combinations of HLA gene variants (HLA haplotypes) have been found to increase the risk of developing celiac disease, a disorder in which inflammation damages the intestinal tract and other organs and tissues. One of these haplotypes, known as DQ2, is composed of the protein produced from HLA-DQA1 gene variants known as HLA-DQA1*05:01 or HLA-DQA1*05:05 bound to the protein produced from HLA-DQB1 gene variants known as HLA-DQB1*02:01 or HLA-DQB1*02:02. The other haplotype, known as DQ8, is composed of the protein produced from HLA-DQA1 gene variants known as HLA-DQA1*03:01 or HLA-DQA1*03:02 bound to the protein produced from the HLA-DQB1 gene variant known as HLA-DQB1*03:02. The DQ2 and DQ8 haplotypes, which may occur separately or together, seem to increase the risk of an inappropriate immune response to the protein gluten, which is found in wheat, rye, and barley.

This immune system malfunction results in the damage to the body’s organs and tissues that occurs in celiac disease. However, the DQ2 and DQ8 haplotypes are also found in 30 percent of the general population, and only 3 percent of individuals with these haplotypes develop celiac disease. idiopathic inflammatory myopathy Genetics Home Reference provides information about idiopathic inflammatory myopathy. juvenile idiopathic arthritis Genetics Home Reference provides information about juvenile idiopathic arthritis. narcolepsy Genetics Home Reference provides information about narcolepsy. type 1 diabetes Combinations of variations in the HLA-DQA1 gene and other HLA genes affect the risk of type 1 diabetes.

Type 1 diabetes is characterized by high blood sugar levels resulting from a shortage of the hormone insulin and is caused by autoimmune damage to insulin-producing cells in the pancreas. Type 1 diabetes risk is most increased by two HLA haplotypes involving variations of the HLA-DQA1 and HLA-DQB1 genes and another HLA gene called HLA-DRB1. One haplotype, written as DRB1*03:01-DQA1*05:01-DQB1*02, is called DR3. The other haplotype, written as DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*02, is called DR4. People at highest risk of developing type 1 diabetes have one copy of the DR3 haplotype and one copy of the DR4 haplotype in each cell.

Other HLA haplotypes only mildly increase the risk of type 1 diabetes, while some haplotypes seem to protect against developing this condition. Variations in other genes and environmental factors are also thought to affect the risk of this complex disorder, autoimmune disorders Certain normal variations of the HLA-DQA1 gene have been associated with increased risk of autoimmune disorders, which occur when the immune system malfunctions and attacks the body’s own tissues and organs.

It is unclear how different versions of the HLA-DQA1 gene influence the risk of developing autoimmune disorders. These conditions are thought to result from a combination of multiple environmental and genetic factors.

Changes in other HLA and non-HLA genes, some of which remain unknown, also likely contribute to the risk of developing these complex conditions. other disorders Normal variations in the HLA-DQA1 gene can affect the body’s ability to recognize and react to foreign invaders (pathogens).

Variations of this gene have been shown to increase or decrease a person’s chance of getting infections such as hepatitis B and leprosy or may affect the severity of illness if infection occurs. A particular variant of the HLA-DQA1 gene known as HLA-DQA1*02:01 increases the risk of liver damage in women with advanced breast cancer treated with a drug called lapatinib. Researchers suggest that the variant may increase immune system sensitivity to the drug, resulting in inflammation that damages the liver.

The HLA-DQA1 gene provides instructions for making a protein that plays a critical role in the immune system.

The HLA-DQA1 gene is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body’s own proteins from proteins made by foreign invaders such as viruses and bacteria.

The HLA complex is the human version of the major histocompatibility complex (MHC), a gene family that occurs in many species. The HLA-DQA1 gene belongs to a group of MHC genes called MHC class II. MHC class II genes provide instructions for making proteins that are present on the surface of certain immune system cells.

These proteins attach to protein fragments (peptides) outside the cell. MHC class II proteins display these peptides to the immune system. If the immune system recognizes the peptides as foreign (such as viral or bacterial peptides), it triggers a response to attack the invading viruses or bacteria.

The protein produced from the HLA-DQA1 gene attaches (binds) to the protein produced from another MHC class II gene, HLA-DQB1. Together, they form a functional protein complex called an antigen-binding DQαβ heterodimer.

This complex displays foreign peptides to the immune system to trigger the body’s immune response. Each MHC class II gene has many possible variations, allowing the immune system to react to a wide range of foreign invaders. Researchers have identified hundreds of different versions (alleles) of the HLA-DQA1 gene, each of which is given a particular number (such as HLA-DQA1*05:01).

Gene function

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues.

The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases.

Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components.

Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer.

Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide).

The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO.

Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Disease association

Advanced information

The following transcription factors affect gene expression (R):

  • c-Myc
  • STAT1
  • STAT1alpha
  • STAT1beta
  • c-Rel

Gene Pathways:

  • Immune System
  • Systemic lupus erythematosus
  • Antigen processing and presentation
  • Type I diabetes mellitus
  • Intestinal immune network for IgA production
  • Autoimmune thyroid disease
  • Asthma
  • Phagosome
  • Graft-versus-host disease
  • Viral myocarditis
  • Cell adhesion molecules (CAMs)
  • Rheumatoid arthritis
  • Tuberculosis
  • Leishmaniasis
  • Staphylococcus aureus infection
  • Toxoplasmosis
  • Allograft rejection

Molecular Function:

  • Mhc Class Ii Receptor Activity
  • Peptide Antigen Binding

Biological Processes:

  • Antigen Processing And Presentation Of Exogenous Peptide Antigen Via Mhc Class Ii
  • Immune Response
  • Interferon-Gamma-Mediated Signaling Pathway
  • T Cell Costimulation
  • T Cell Receptor Signaling Pathway

Synonyms/Aliases/Alternative Names of the Gene:

CELIAC1| DC-1 alpha chain| DC-alpha| DQ-A1| HLA class II histocompatibility antigen, DQ alpha 1 chain| HLA-DCA| HLA-DQA| major histocompatibility complex, class II, DQ alpha 1-like| Mamu-DQA| MHC class II antigen| MHC class II DQA1| MHC class II HLA-DQ-alpha-1| MHC HLA-DQ alpha| hla-dqa1| hypothetical protein